Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2016 May 9;15(7):1485–1494. doi: 10.1158/1535-7163.MCT-15-0566

Figure 1. GS87 is a highly specific and potent GSK3 inhibitor that induces AML cell differentiation.

Figure 1

(A) Molecular structure of GS87. (B) GS87 is a potent GSK3 inhibitor. In vitro kinase assay for GSK3α and GSK3β. (C) GS87 leads to extensive AML differentiation as measured by respiratory burst capacity. OCI, HL-60, and NB4 cells were treated with GS87 (30μM), Li (10mM) or SB (20μM) for 72 hours and differentiation capacity was measured using the NBT reduction assay. (D) GS87 leads to more effective AML differentiation than other clinically used GSK3 inhibitors. HL-60 cells were treated with GS87 (30μM), Tideglusib (30μM) or LY-2090314 (30μM) for 72 hours and differentiation was measured by the NBT assay. * p<.05; **p<.01